5 completed, 2 terminated. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Terminated 2 |
Follow Refractory Malignant Neoplasm: new trials by email Literature Review of Refractory Malignant Neoplasm trials Research Report on Refractory Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Bevacizumab, Fluorouracil, Leucovorin - Advanced Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver | Phase 1 | Terminated | M.D. Anderson Cancer Center | 38 | 2020-06-23 | 2026-07-27 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer Antiretroviral Therapy, Biopsy, Biospecimen Collection - AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Completed | National Cancer Institute (NCI) | 58 | 2016-04-04 | 2024-08-09 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study - Cirrhosis, Hepatitis B Infection | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-01-30 | 2024-11-22 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 154 | 2012-10-16 | 2026-05-15 |
| Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers Anakinra, Denosumab, Everolimus - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 57 | 2012-06-19 | 2021-02-25 |
| Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 123 | 2012-05-14 | 2026-08-28 |
| Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Malignant Neoplasm, BRAF Gene Mutation | Phase 1 | Completed | M.D. Anderson Cancer Center | 46 | 2012-02-06 | 2021-01-22 |
Neoplasms (7) · Neoplasm Metastasis (6) · Recurrence (5) · Carcinoma, Hepatocellular (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Castleman Disease (1) · Endocrine Gland Neoplasms (1) · Erdheim-Chester Disease (1) · Fibrosis (1) · HIV Infections (1) · Hepatitis B (1) · Hepatitis C (1) · Lung Neoplasms (1)
Neoplastic Processes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Disease Attributes (5) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Blood-Borne Infections (2) · Communicable Diseases (2) · DNA Virus Infections (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Hemic and Lymphatic Diseases (2)
Bevacizumab (2) · Disulfides (2) · Everolimus (2) · Immunoglobulin G (2) · Sirolimus (2) · Sorafenib (2) · temsirolimus (2) · Antiretroviral Therapy, Highly Active (1) · Biopsy (1) · Cetuximab (1) · Crizotinib (1) · Denosumab (1) · Doxorubicin (1) · Fluorouracil (1) · Interleukin 1 Receptor Antagonist Protein (1)
M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (2)
United States (7)
Filip Janku (2) · Brian A Costello (1) · Kathryn Lurain (1) · Sarina A Piha-Paul (1) · Sarina Piha-Paul, MD (1) · Siqing Fu (1)
PMID 25982012, PMID 31154457, PMID 35080914, PMID 37311055, PMID 39356983, PMID 41389341, PMID 41680482
P30CA016672 (2), P30CA015704 (1), U01CA154967 (1), UM1CA186686 (1)